#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Upstream therapy of atrial fibrillation


Authors: R. Lábrová;  J. Špinar
Authors‘ workplace: Interní kardiologická klinika LF MU a FN Brno
Published in: Kardiol Rev Int Med 2011, 13(3): 160-166

Overview

Triggering ectopias and arrhytmogenic substrates that enable the preservation of atrial fibrillation are related to electrical, structural and subsequent mechanical remodelling of the atrial myocardium and are significantly affected by a number of modulating factors. The presence of atrial fibrillation itself accelerates the remodelling process. So called ‘upstream therapy’ interferes with the pathogenesis of atrial fibrillation as well as with the remodelling process and is administered in both primary and secondary preventive care. The renin-angiotensin-aldosterone system plays an important role in the pathogenesis and preservation of atrial fibrillation and significantly influences the process of electrical and structural remodelling. Effective inhibition of the renin-angiotensin-aldosterone system may help prevent the genesis and recurrence of atrial fibrillation, therefore reducing ne­gative effects associated with the presence of atrial fibrillation. Upstream therapy is clearly indicated in patients with hypertension, particularly with left ventricle hypertrophy, and in cardiac failure patients with left ventricular dysfunction. In these cases therapy is indicated also without regard to atrial fibrillation. Evidence is less supportive of upstream therapy for patients with minimal structural impairment of the heart or in secondary preventive care. Statins with anti-inflammatory effects are indicated in the primary prevention of atrial fibrillation in post-operative conditions, particularly following coronary by-pass operations or valvular repairs. The introduction of statins may be considered for patients with heart failure, hypertension and ischaemic heart disease. Renin-angiotensin-aldosterone system blockers and statins are not indicated in primary prevention for patients without cardiovascular disease. The positive effects of various anti-inflammatory drugs, corticosteroids, polyunsaturated fatty acids and other substances on atrial fibrillation have not been proven and as such are not indicated in the upstream therapy concept.

Keywords:
atrial fibrillation – atrial remodelling – upstream therapy – angiotensin-converting enzyme inhibitors – angiotensin receptor blockers – statins – steroids – polyunsaturated fatty acids


Sources

1. Stewart S, Murphy N, Walker A et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004; 90: 286–292.

2. Tsang TS, Petty GW, Barnes ME et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol 2003; 42: 93–100.

3. McGovern PG, Jacobs DR Jr, Shahar E et al. Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota Heart Survey. Circulation 2001; 104: 19–24.

4. Lábrová R. Fibrilace síní v době katétrové ablace. Vnitř Lék 2010; 56: 871–879.

5. Savelieva I, Camm AJ. Is there any hope for angio­tensin-converting enzyme inhibitors in atrial fibrillation? Am Heart J 2007; 154: 403–406.

6. Feng J, Yue L, Wang Z et al. Ionic mechanism of regional action potential heterogeneity in the canine right atrium. Circ Res 1998; 83: 541–551.

7. Bosch RF, Scherer CR, Rüb NL et al. Molecular mechanisms of early electrical remodeling: transcriptional downregulation of ion channel subunits deduces I (Ca,L) an I(to) in rapid atrial pacing in rabbits. J Am Coll Cardiol 2003; 41: 858–869.

8. Madrid AH, Escobar C, Rebollo JM et al. Angiotensin receptor blocker as adjunctive therapy for rhythm control in atrial fibrillation: results of the irbesartan-amiodarone trial. Card Electrophysiol Rev 2003; 7: 243–246.

9. Douglas P. The left atrium: a biomarker of chronic diastolic dysfunction and cardiovascular disease risk. J Am Coll Cardiol 2002; 42: 1206–1207.

10. Morillo CA, Klein GJ, Jones DL et al. Chronic rapid atrial pacing. Structural, functional, and electrophysio­logical characteristics of a new model of sustained atrial fibrillation. Circulation 1995; 91: 1588–1595.

11. Goette A, Arndt M, Röcken C et al. Regulation of angiotension II receptors subtypes during atrial fibrillation in humans. Circulation 2000; 101: 2678–2681.

12. Freestone B, Beevers DG, Lip GY. The renin-angiotensin-aldosterone system in atrial fibrillation: a ne therapeutic target? J Hum Hypertens 2004; 18: 461–465.

13. Das UN. Is angiotensin-II an endogenous pro-inflammatory molecule? Med Sci Monit 2005; 11: 155–162

14. Healey JS, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45: 1832–1839.

15. Magioni AP, Latini R, Carson PE et al. Val HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val HeFT). Am Heart J 2005; 149: 548–557.

16. Olsson LG, Swedberg K, Duchampe A et al. CHARM Investigators. Atrial fibrillation and risk of clinical event in chronic heart failure with and without left ventricular dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006; 46: 1997–2004.

17. Zhang Y, Zhang P, MuY et al. The role of renin-angiotenzin blockade therapy in prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Clin Pharmacol Ther 2010; 88: 521–531.

18. Špinar J, Vítovec J. Inhibitory ACE, nebo sartany v léčbě pacientů po infarktu myokardu. Cor Vasa 2009; 51: 103–111.

19. Pedersen OD, Bagger H, Kober L et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 376–380.

20. Yusuf S, Sleight P, Pogue J et al. The HOPE investigators. Effects of angiotensin-converting-enzyme inhibitor ramipril, on cardiovscular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–153.

21. Vermes E, Tardif JC, Bourassa MG et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction. Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926–2931.

22. Wachtel K, Hornestam B, Lehto M et al. Cardiovascular morbidity and mortality in hypertensive pa­tients with a history of atrial fibrillation: The Losartan Intervention For Endpoints reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 705–711.

23. Wachtel K, Lehto M, Olsen MH et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For Endpoints reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712–719.

24. Ueng KC, Tsai TP, Yu WC et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of prospective and cotrolled study. Eur Heart J 2003; 24: 2090–2098.

25. Madrid AH, Bueno MG, Rebollo JMG et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 331.

26. Belluzzi F, Sernesi L, Preti P et al. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 2009; 53: 24–29.

27. Disertori M, Latini R, Barlera S et al. GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360: 1606–1617.

28. ACTIVE I Investigators. Yusuf S, Healey JS, Pogue J et al. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011; 364: 928–938.

29. Špinar J, Lábrová R. ACTIVE I a upstream terapie. Interv Akut Kardiol 2009; 8: 325–327

30. Savelieva I, Camm AJ. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med 2008; 5: 30–41.

31. Patti G, Chello M, Candura M et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhytmia After cardiac surgery) study. Circulation 2006; 114: 1456–1461.

32. Young-Xu Y, Jabbour S, Goldberg R et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92: 1379–1383.

33. Calò L, Bianconi L, Colivicchi F et al. N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 2005; 45: 1723–1728.

34. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004; 25: 1100–1107.

35. Cheruku KK, Ghani A, Ahmad F et al. Efficacy of nonsteroidal anti-inflammatory medications for prevention of atrial fibrillation following coronary artery bypass graft surgery. Prev Cardiol 2004; 7: 13–18.

36. Zhang Y, Zhang P, MuY et al. The role of renin-angiotenzin blockade therapy in prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Clin Pharmacol Ther 2010; 88: 521–531.

37. Camm AJ, Kirchhof P, Lip GY et al. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369–2429.

Labels
Paediatric cardiology Internal medicine Cardiac surgery Cardiology
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#